NIHR BioResource

NIHR BioResource is a unique and powerful resource for studying disease mechanisms and for investigating the links between genes, the environment, health and disease; enabling scientific discoveries as well as facilitating translational medicine for the benefit of patients. Our mission is to facilitate human health research and its transformation into medical practice. We have over 270,000 consented volunteers, from the general population and patients with common and rare diseases. BioResource volunteers are willing to be recalled according to their genotype and/or phenotype and to participate in academic and industry-led experimental medicine and clinical research studies. Participants who join the NIHR BioResource donate their DNA via a blood or saliva sample which is used together with other information (e.g. gender, ethnicity, health records, genomics), to match them to specific research studies. Genotyping information via high density array is available for most of the BioResource panel, and many of those with rare diseases have whole genome sequencing data available. Where blood samples were taken, plasma, serum and whole blood samples are banked and - along with underlying data - these samples may be requested through our approvals process, see https://bioresource.nihr.ac.uk/using-our-bioresource/apply-for-bioresource-data-access/ As well as healthy volunteers (GEN), the NIHR BioResource has enrolled over 24,000 patients with Rare Diseases (RD), and has four established cohorts, including mental health (MH), Inflammatory Bowel Disease (IBD), Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD, previously known as Non-Alcoholic Fatty Liver Disease - NAFLD) and Immune-Mediated Inflammatory Diseases (IMID). We also created a COVID-19 BioResource which has samples and health data from patients, health workers and visitors to screening pods, vaccination and long COVID clinics. Our newest cohort is the DNA + Young People's Health Resource (D-CYPHR) focused on those aged under 16. Programmes with blood derived banked samples (Plasma, Serum, DNA): General Population 135,000 participants; Genotype array data and Health and Lifestyle questionnaire data available. Inflammatory Bowel Disease (IBD) 45,500 participants; Genotype array data, WES/WGS data, Health and Lifestyle questionnaire data and clinical data available. Immune-Mediated Inflammatory Diseases (IMID) 15,000 participants; Genotype array data pending, Health and Lifestyle questionnaire data and clinical data available. Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD, previously Non-Alcoholic Fatty Liver Disease - NAFLD) 3,500 participants: Genotype array data pending, Health and Lifestyle questionnaire data and clinical data available. Rare Diseases (RD) >24,000 participants; Genotype array data, WGS data, Health and Lifestyle questionnaire data and clinical data available. COVID-19 >8,000 participants; Genotype array data, Health and Lifestyle questionnaire data and clinical data available. Programmes with saliva derived banked samples (DNA): Mental Health (MH) 35,000 participants; Genotype array data, Health and Lifestyle questionnaire data and clinical data available. DNA + Young People's Health Resource (D-CYPHR) >1,000 participants with Health and Lifestyle questionnaire data; Genotype array data pending. Researchers can apply for access to Samples, Data and/or volunteer access (Recall) as specific study requests. Recall could include contacting volunteers with questionnaires or clinical appointments to obtain bespoke samples (from easily accessible sites e.g. urine, skin biopsy) or to take part in activities like an MRI or exercise test. Please contact us if you have a research interest in any disorders or sample types outside of those listed as our core cohorts, we can mine the demographic, genetic and clinical data held to determine if we have suitable candidates for recall to generate the bespoke samples/ data required. Applications are reviewed by a scientific steering committee and delivery timelines will depend on current demand and the complexity of the study. Industry partners may encounter a cost to access NIHR BioResource volunteers. A detailed cost for Industry-led studies can be found at: https://bioresource.nihr.ac.uk/using-our-bioresource/costs/ The Annual Statistics table only lists access requests for banked samples in the March to March period used for HTA reporting, some studies are ongoing requests requiring multiple shipments and are reported in multiple years. A higher proportion of researchers request data access or recall studies than banked samples. We also contribute to the UK LLC and HDR UK (Gut Reaction) national programmes.

Services

  • Ability to recontact
  • Data analytics
  • Nucleic acid extraction

Existing samples:

  • Depressive disorder (disorder)
  • Fit and well (finding)
  • Inflammatory bowel disease (disorder)

Bespoke collection capabilities:

  • Attention deficit hyperactivity disorder (disorder)
  • Depressive disorder (disorder)
  • Diabetes mellitus type 1 (disorder)
  • Diabetes mellitus type 2 (disorder)
  • Fibromyalgia (disorder)
  • Fit and well (finding)
  • Hyperlipidemia (disorder)
  • Hypertensive disorder, systemic arterial (disorder)
  • Hypothyroidism (disorder)
  • Inflammatory bowel disease (disorder)
  • Ischemic heart disease (disorder)
  • Migraine (disorder)
  • Multiple sclerosis (disorder)
  • Parkinson's disease (disorder)

Contact Information

Email:
nbr@bioresource.nihr.ac.uk
Telephone:
0800 090 2233
Address:

NIHR BioResource, Box 299
University of Cambridge and Cambridge University Hospitals NHS Foundation Trust
Cambridge Biomedical Campus
Hills Road
Cambridge
Cambridgeshire
CB2 0QQ
England

Last Updated: 06/18/2024


Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 0 1 0 0 1 0
2018 0 9 0 0 9 0
2019 0 6 0 0 4 0
2020 0 14 0 0 13 0
2021 11 12 0 11 12 0
2022 N/A N/A N/A N/A N/A N/A
2023 N/A N/A N/A N/A N/A N/A
2024 N/A N/A N/A N/A N/A N/A